Healthcare / Drug Manufacturers - GeneralNYSE
$115.17
-3.55 (-2.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $12.4B · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$284.4B
P/E
32.4x
↑EV/EBITDA
11.4x
↓ROE
34.7%
↑Gross Margin
74.8%
↑Debt/Equity
0.94
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
+5.6%
FCF CAGR
—
FCF margin
19.0%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $65.01B · net income $18.25B · FCF $12.36B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $65.01B | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B | $41.52B | $39.12B | $42.29B | $40.12B | $39.81B | — | — | — | — | — | $45.99B | $27.43B | $23.85B | $24.20B |
| Net Income | $18.25B | $18.25B | $17.12B | $365.0M | $14.52B | $13.05B | $7.07B | $9.84B | $6.22B | $2.39B | $3.92B | $4.44B | $11.92B | $4.40B | $6.17B | $6.27B | $861.0M | $12.90B | $7.81B | $3.28B |
| EBITDA | $28.26B | $28.26B | $25.71B | $6.91B | $21.32B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | 7.28 | 7.28 | 6.74 | 0.14 | 5.71 | 5.14 | 2.78 | 3.81 | 2.21 | 0.83 | 1.35 | 1.49 | 3.88 | 1.40 | 1.91 | 1.93 | 0.27 | 5.39 | 3.46 | 1.42 |
| Gross Margin | 74.8% | 74.8% | 76.3% | 73.2% | 70.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 34.0% | 34.0% | 31.5% | 4.9% | 30.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | 28.1% | 28.1% | 26.7% | 0.6% | 24.5% | 26.8% | 17.0% | 25.2% | 14.7% | 6.0% | 9.8% | — | — | — | — | — | 1.9% | 47.0% | 32.7% | 13.5% |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 0.94 | 0.94 | 0.80 | 0.93 | 0.67 | 0.80 | 1.00 | 0.88 | 0.74 | 0.62 | 0.61 | 0.53 | 0.38 | 0.41 | 0.31 | 0.28 | 0.28 | 0.27 | 0.21 | — |
| Current Ratio | 1.30 | 1.30 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $12.36B | $12.36B | $18.10B | $9.14B | $14.71B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||||
| ROE | 34.7% | 34.7% | 37.0% | 1.0% | 31.6% | 34.2% | 27.9% | 38.0% | 23.3% | 7.0% | 9.8% | 9.9% | 24.5% | 8.8% | 11.6% | 11.5% | 1.6% | 21.8% | 41.6% | — |
| Valuation | ||||||||||||||||||||
| P/E | 32.44 | 32.44 | 14.71 | 837.29 | 20.11 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 11.45 | 11.45 | 10.73 | 48.33 | 14.54 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 5.49 | 5.49 | 5.44 | 8.13 | 6.35 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 1.3% | 1.3% | 6.7% | 1.4% | — | 17.3% | 6.1% | -7.5% | 5.4% | 0.8% | — | — | — | — | — | — | 67.7% | 15.0% | -1.4% | — |
| EPS Growth | 8.0% | 8.0% | 4714.3% | -97.5% | — | 84.9% | -27.0% | 72.1% | 166.7% | -38.3% | -9.6% | -61.7% | 176.9% | -26.5% | -1.0% | 621.4% | -95.0% | 55.6% | 143.6% | — |
| Dividend Yield | 2.9% | 2.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
12.0%
EPS terminal req.
$10.22
Spread vs growth
-4.0%
5Y implied EPS CAGR
11.2%
EPS terminal req.
$12.37
Spread vs growth
-3.2%
10Y implied EPS CAGR
10.6%
EPS terminal req.
$19.91
Spread vs growth
-2.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+52.8%
Start / end P/E
11.4x → 15.8x
EPS bridge
6.74 → 7.28
Residual
+3.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.